Reduced all-cause mortality with bisphosphonates among post-fracture osteoporosis patients: a nationwide study and systematic review
In conclusion, bisphosphonate use, especially persistence to intravenous bisphosphonates (e.g., zoledronic acid), may reduce post-fracture mortality among osteoporosis patients, particularly those with hip/vertebral fractures. This supports the rational use of bisphosphonates in post-fracture care.PMID:35561128 | DOI:10.1002/cpt.2645 (Source: Clinical Pharmacology and Therapeutics)
Source: Clinical Pharmacology and Therapeutics - May 13, 2022 Category: Drugs & Pharmacology Authors: Yu-Hsuan Hsu Chia-Chun Li Fu-Wen Liang Zi-Yang Peng Yin-Fan Chang Jason C Hsu Huang-Tz Ou Chih-Hsing Wu Source Type: research
Reduced all-cause mortality with bisphosphonates among post-fracture osteoporosis patients: a nationwide study and systematic review
In conclusion, bisphosphonate use, especially persistence to intravenous bisphosphonates (e.g., zoledronic acid), may reduce post-fracture mortality among osteoporosis patients, particularly those with hip/vertebral fractures. This supports the rational use of bisphosphonates in post-fracture care.PMID:35561128 | DOI:10.1002/cpt.2645 (Source: Clinical Pharmacology and Therapeutics)
Source: Clinical Pharmacology and Therapeutics - May 13, 2022 Category: Drugs & Pharmacology Authors: Yu-Hsuan Hsu Chia-Chun Li Fu-Wen Liang Zi-Yang Peng Yin-Fan Chang Jason C Hsu Huang-Tz Ou Chih-Hsing Wu Source Type: research
An open ‐label randomized study of the relative absorption of gastro‐resistant risedronate taken fasted or with food versus immediate‐release risedronate
This study compared the relative absorption of four formulations of gastro-resistant risedronate 35 mg (formulations 1 –4) taken fasted or with food vs. immediate-release risedronate 35 mg taken fasted. AbstractPatients with osteoporosis often take oral bisphosphonates with food, rendering these medications ineffective. This study compared the relative absorption of four formulations of gastro-resistant (GR; formulations 1 –4) risedronate 35 mg versus immediate-release (IR) risedronate 35 mg taken fasted. Secondarily, it compared the relative absorption of GR formulations administered fed and fasted, and determined t...
Source: Pharmacology Research and Perspectives - May 9, 2022 Category: Drugs & Pharmacology Authors: Diane Kleinermans,
Andrew Joyson,
Heather Wray Tags: ORIGINAL ARTICLE Source Type: research
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women
CONCLUSIONS: This update recaps the key findings from our previous review that, for secondary prevention, risedronate 5 mg/day probably prevents non-vertebral fracture, and may reduce the risk of hip fractures. We are uncertain on whether risedronate 5mg/day reduces clinical vertebral and wrist fractures. Compared to placebo, risedronate probably does not increase the risk of serious adverse events. For primary prevention, the benefit and harms of risedronate were supported by limited evidence with high uncertainty.PMID:35502787 | DOI:10.1002/14651858.CD004523.pub4 (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - May 3, 2022 Category: General Medicine Authors: George A Wells Shu-Ching Hsieh Carine Zheng Joan Peterson Peter Tugwell Wenfei Liu Source Type: research
Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada
ConclusionRomosozumab/alendronate was associated with reduced costs and greater benefit relative to other comparators. Probabilistic, deterministic, and scenario analyses indicate that romosozumab/alendronate represents the best value for money; the uncertainty analyses are robust, and therefore romosozumab should be considered for reimbursement by public drug plans in Canada
. (Source: Archives of Orthopaedic and Trauma Surgery)
Source: Archives of Orthopaedic and Trauma Surgery - April 26, 2022 Category: Orthopaedics Source Type: research
Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment
ABSTRACTIn a randomized clinical trial in patients initiating glucocorticoid therapy (GC-I) or on long-term therapy (GC-C), denosumab every 6 months increased spine and hip bone mineral density at 12 and 24 months significantly more than daily risedronate. The aim of this study was to evaluate the effects of denosumab compared with risedronate on bone strength and microarchitecture measured by high-resolution peripheral quantitative computed tomography (HR-pQCT) in GC-I and GC-C. A subset of 110 pati ents had high-resolution peripheral quantitative computed tomography (HR-pQCT) scans of the distal radius and tibia at bas...
Source: Journal of Bone and Mineral Research - April 20, 2022 Category: Orthopaedics Authors: Piet Geusens,
Melissa SAM Bevers,
Bert Rietbergen,
Osvaldo D Messina,
Eric Lespessailles,
Beatriz Oliveri,
Roland Chapurlat,
Klaus Engelke,
Arkadi Chines,
Shuang Huang,
Kenneth G Saag,
Joop P Bergh Tags: Clinical Trial Source Type: research
Comorbidity and osteoporotic fracture: approach through predictive modeling techniques using the OSTEOMED registry
CONCLUSION: In general, sex, age and the number of comorbidities did not influence the likelihood that a given anti-osteoporotic treatment improved the risk of incident fragility fractures after 1 year, but this appeared to increase when patients had been treated with risedronate, strontium or teriparatide. The two models used classified patients similarly, but predicted differently in terms of the probability of improvement, with logistic regression being the better fit.PMID:35435583 | DOI:10.1007/s40520-022-02129-5 (Source: Aging Clinical and Experimental Research)
Source: Aging Clinical and Experimental Research - April 18, 2022 Category: Geriatrics Authors: Mar ía Begoña Coco Martín Luis Leal Vega Jos é Antonio Blázquez Cabrera Amalia Navarro Mar ía Jesús Moro Francisca Arranz Garc ía Mar ía José Amérigo Manuel Sosa Henr íquez Mar ía Ángeles Vázquez Mar ía José Montoya Manuel D íaz Curiel J Source Type: research
Comorbidity and osteoporotic fracture: approach through predictive modeling techniques using the OSTEOMED registry
CONCLUSION: In general, sex, age and the number of comorbidities did not influence the likelihood that a given anti-osteoporotic treatment improved the risk of incident fragility fractures after 1 year, but this appeared to increase when patients had been treated with risedronate, strontium or teriparatide. The two models used classified patients similarly, but predicted differently in terms of the probability of improvement, with logistic regression being the better fit.PMID:35435583 | DOI:10.1007/s40520-022-02129-5 (Source: Aging Clinical and Experimental Research)
Source: Aging Clinical and Experimental Research - April 18, 2022 Category: Geriatrics Authors: Mar ía Begoña Coco Martín Luis Leal Vega Jos é Antonio Blázquez Cabrera Amalia Navarro Mar ía Jesús Moro Francisca Arranz Garc ía Mar ía José Amérigo Manuel Sosa Henr íquez Mar ía Ángeles Vázquez Mar ía José Montoya Manuel D íaz Curiel J Source Type: research
Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis
CONCLUSIONS This study found that romosozumab yielded the best effects for preventing fracture risk, while abaloparatide was the most effective in reducing the risk of vertebral fracture and non-vertebral fracture.PMID:35430576 | DOI:10.12659/MSM.935491 (Source: Medical Science Monitor)
Source: Medical Science Monitor - April 17, 2022 Category: Research Authors: Jiping Shen Zheng Ke Shuangshuang Dong Minzhi Lv Ying Yuan Le Song Kefen Wu Kan Xu Yu Hu Source Type: research
Comment on "The efficiency of risedronate in reducing bone resorption after total hip arthroplasty: a meta-analysis of randomized control trials at a minimum of 6 months' follow-up"
J Orthop Surg Res. 2022 Apr 12;17(1):231. doi: 10.1186/s13018-022-03118-0.NO ABSTRACTPMID:35414097 | DOI:10.1186/s13018-022-03118-0 (Source: Cell Research)
Source: Cell Research - April 13, 2022 Category: Cytology Authors: M M Kai Huang M M Gang Wang M D Yi Zeng Source Type: research
Comment on “The efficiency of risedronate in reducing bone resorption after total hip arthroplasty: a meta-analysis of randomized control trials at a minimum of 6 months’ follow-up”
(Source: Journal of Orthopaedic Surgery and Research)
Source: Journal of Orthopaedic Surgery and Research - April 12, 2022 Category: Orthopaedics Authors: M. M. Kai Huang, M. M. Gang Wang and M. D. Yi Zeng Tags: Letter to the Editor Source Type: research
Endoplasmic Reticulum Stress Mediates Renal Tubular Vacuolation in BK Polyomavirus-Associated Nephropathy
ConclusionERS was involved in renal tubular cytoplasmic vacuolation in BKPyVAN recipients. Risedronate was screened as a potential drug for BKPyVAN by targeting DDIT3. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - April 8, 2022 Category: Endocrinology Source Type: research
